Patients with moderate to severe atopic dermatitis experienced a 71% decrease in Eczema Area and Severity Index scores from ...

A new trial finds guselkumab is highly effective and well tolerated for moderate to severe scalp psoriasis in individuals ...

Lebrikizumab provided sustained itch relief and improved sleep quality through 52 weeks in individuals with ...

Apogee's APG777 showed a 71% drop in eczema severity and strong itch relief in a Phase 2 trial for atopic dermatitis. Part B ...

Among patients who had moderate-to-severe pruritus, mean change from baseline to week 52 on the Worst Itch Numeric Rating Scale did not significantly differ between the elafibranor and placebo groups.

In addition, itch was improved, with 30.9% of participants 6 years and over and 41.2% of participants 2 to 5 years achieving clinically meaningful reduction in Worst Itch Numeric Rating Scale (WI ...

ZORYVE foam provided a clinically meaningful improvement in scalp itch. 65.3% of individuals treated with ZORYVE achieved a clinically significant reduction in itch compared to 30.3% of individuals ...

The data also demonstrated improvement in body itch as measured by the Worst Itch-Numeric Rating Scale (WI-NRS) at Week 8, with 63.1% of those treated with ZORYVE foam 0.3% achieving a ≥ 4-point ...

Additionally, skin pain, as assessed by the Skin Pain Numeric Rating Scale (NRS), showed significant improvement, with 58.8% of patients achieving at least a 4-point reduction at week 16 and 75.0% at ...

Disclosure: Gelhorn is an employee of Evidera, which was funded by GSK to carry out the study ‘Validation Of The Worst Itch Numerical Rating Scale (WI-NRS) And Related Patient-Reported Outcomes (PROs) ...

Incyte's Phase 3 TRuE-PN trials show ruxolitinib cream improves itch relief in prurigo nodularis, though TRuE-PN2's primary endpoint fell short.